We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining

◀ Back to NOS3

EDN3 — NOS3

Text-mined interactions from Literome

Barton et al., J Am Soc Nephrol 2000 (Glomerulosclerosis, Focal Segmental...) : Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension : mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis
Ye et al., Hypertension 2003 : We asked whether endothelin might play a role in the control of basal or osmotically regulated NPR-A or eNOS gene expression in these cells ... Increased extracellular tonicity reduced endothelin mRNA accumulation in these cells ( approximately 15 % of control levels ) ; however, exogenous endothelin failed to normalize osmotically increased NPR-A activity or expression, or osmotically suppressed eNOS expression
Sudjarwo et al., Eur J Pharmacol 1992 : These results suggest that ET-3 acts on ETB receptors in the vascular endothelium to increase [Ca2+ ] i by releasing Ca2+ from storage sites and by opening non-L type Ca2+ channels, activates nitric oxide synthase , releases nitric oxide and relaxes vascular smooth muscle
Ohlstein et al., J Neurosurg 1992 : An l-arginine analog inhibitor of nitric oxide synthase , L-NG-monomethyl arginine ( L-NMMA, 200 microM ), did not significantly affect basal immunoreactive endothelin levels
Novella et al., Eur J Cardiothorac Surg 2007 (Cardiovascular Diseases) : No change in the AVP response was produced by endothelium removal, exposure to the NO precursor ( 3 x 10 ( -4 ) M L-arginine ), inhibition of nitric oxide ( NO ) synthase ( 3 x 10 ( -5 ) M L-NAME ) or soluble guanylate cyclase ( 3 x 10 ( -6 ) M 1H- [ 1,2,4 ] oxadiazol [ 4,3,-alpha ] quinoxalin-1-one ( ODQ ) ), removal of the superoxide anion ( 100 U/ml superoxide dismutase ( SOD ) plus 1200 U/ml catalase ) or hydroxyl radical ( 10 ( -4 ) M deferoxamine ), or specific alpha1 - ( 10 ( -6 ) M prazosin ) or endothelin ( 10 ( -5 ) M bosentan ) receptor antagonism
Chandrasekar et al., Pediatr Res 2008 (Disease Models, Animal...) : PPHN was associated with decreases in eNOS and ET-B receptor and increase in prepro-endothelin mRNA levels
Lin et al., Eur J Endocrinol 1998 : Role of nitric oxide synthase in release of endothelin from cultured human endometrial cells